Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, December 24 through Wednesday, December 26 inclusive. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 29.08.16 in Vol 5, No 3 (2016): Jul-Sept

This paper is in the following e-collection/theme issue:

Works citing "Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6046):

(note that this is only a small subset of citations)

  1. Hurtado RM, Meressa D, Goldfeld AE. Treatment of drug-resistant tuberculosis among people living with HIV. Current Opinion in HIV and AIDS 2018;13(6):478
    CrossRef
  2. Hammoud DA, Boulougoura A, Papadakis GZ, Wang J, Dodd LE, Rupert A, Higgins J, Roby G, Metzger D, Laidlaw E, Mican JM, Pau A, Lage S, Wong C, Lisco A, Manion M, Sheikh V, Millo C, Sereti I. Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Human Immunodeficiency Virus–Associated Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases 2018;
    CrossRef
  3. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. New England Journal of Medicine 2018;379(20):1915
    CrossRef